Collectively, our findings provide encouraging evidence of a new therapeutic target to inhibit CSCs-mediated ovarian cancer initiation and progression towards the IL-23/IL-23R/STAT3/NF-κB axis. The gene discussed is NFKB1; the disease is ovarian cancer.